Page last updated: 2024-10-28

hydroxychloroquine and Pneumococcal Infections

hydroxychloroquine has been researched along with Pneumococcal Infections in 1 studies

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Pneumococcal Infections: Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Anton-Vazquez, V1
Clivillé, R1

Other Studies

1 other study available for hydroxychloroquine and Pneumococcal Infections

ArticleYear
Streptococcus pneumoniae coinfection in hospitalised patients with COVID-19.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021, Volume: 40, Issue:6

    Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Alanine; Anti-Bacterial Agents; Anti-Inflam

2021